earnings
confidence high
sentiment neutral
materiality 0.75
Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower
TEVA PHARMACEUTICAL INDUSTRIES LTD
2022-FY EPS reported
-$2.12
revenue$14,925,000,000
- Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.
- Q4 2022 revenues $3.9B; GAAP diluted loss per share $1.10; non-GAAP diluted EPS $0.71.
- 2023 guidance: revenues $14.8-15.4B, non-GAAP diluted EPS $2.25-2.55, free cash flow $1.7-2.1B.
- Goodwill impairment charges of $2.045B and legal settlements of $2.082B recorded in 2022.
- CEO Richard Francis noted AUSTEDO US sales +20% YoY, generics in Europe +9% local currency.